Tg Therapeutics (TGTX) Net Income towards Common Stockholders (2011 - 2026)

Tg Therapeutics' Net Income towards Common Stockholders history runs 16 years deep, the most recent figure standing at $19.8 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 290.23% year-over-year to $19.8 million; the TTM figure through Mar 2026 stood at $462.3 million (up 1055.52% YoY), while the FY2025 annual figure was $447.5 million, up 1744.79% from the prior year.
• Net Income towards Common Stockholders was $19.8 million for Q1 2026 at Tg Therapeutics, down from $23.4 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $390.9 million in Q3 2025 to a low of -$80.4 million in Q4 2022.
• Historically, Net Income towards Common Stockholders has averaged $15.4 million across 5 years, with a median of $3.9 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders sank 96.59% in 2024, then soared 9974.61% in 2025.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$80.4 million in 2022, then surged by 65.18% to -$28.0 million in 2023, then jumped by 186.46% to $24.2 million in 2024, then retreated by 3.39% to $23.4 million in 2025, then retreated by 15.43% to $19.8 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $19.8 million (Q1 2026), $23.4 million (Q4 2025), and $390.9 million (Q3 2025), per Business Quant data.